Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis
NEWARK, Del. and NANJING, China, April 5, 2023. Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced that it has successfully opened an IND following review by the U.S. Food and Drug Administration to...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Biotechnology | China Health | Clinical Trials | Dermatitis | Dermatology | Food and Drug Administration (FDA) | Pharmaceuticals